Catabolism of C1 inhibitor influences the response to replacement therapy in hereditary angioedema.

[1]  L. Terracciano,et al.  Variable asialoglycoprotein receptor 1 expression in liver disease: Implications for therapeutic intervention , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  M. Cicardi,et al.  High‐molecular‐weight kininogen cleavage correlates with disease states in the bradykinin‐mediated angioedema due to hereditary C1‐inhibitor deficiency , 2014, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[3]  M. Triggiani,et al.  Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group , 2014, Allergy.

[4]  B. Zuraw,et al.  Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. , 2012, The American journal of medicine.

[5]  J. Cesbron,et al.  Efficacy of icatibant treatment in patients with hereditary angio‐oedema type I resistant to treatment with C1 inhibitor concentrate , 2011, The British journal of dermatology.

[6]  M. Cicardi,et al.  Relevance of lymphoproliferative disorders and of anti‐C1 inhibitor autoantibodies in acquired angio‐oedema , 1996, Clinical and experimental immunology.

[7]  M. Frank,et al.  Acquired angioedema: observations on the mechanism of action of autoantibodies directed against C1 esterase inhibitor. , 1988, The Journal of allergy and clinical immunology.

[8]  B. Wüthrich,et al.  Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema--evidence of a functionally critical level of C1-inhibitor concentration. , 1984, Complement.

[9]  J. Minta.  The role of sialic acid in the functional activity and the hepatic clearance of C1-INH. , 1981, Journal of immunology.